SHANGHAI – JW Biotechnology (Shanghai) Co. Ltd., a recently formed joint venture (JV) between Juno Therapeutics Inc. and Wuxi Apptec, will continue to develop CAR T treatments for Chinese patients, taking into account the learnings from the halted trials in the U.S. that resulted after three patient deaths. Read More
HONG KONG – China's multibillion-dollar precision medicine initiative is shaping up with a nearly ¥642 million (US$96 million) investment for 61 key projects ready to go. Read More
TOKYO – Japan's Ono Pharmaceutical Co. Ltd. recently got into a public debate at home about the price of its cancer drug, Opdivo (nivolumab), which critics argue could bring too great a burden on the national welfare system. The company, however, said an analyst's estimates as to the amount of people that will use the anti-PD-1 drug and the length of time for which they will use it are both exaggerated. Read More
HONG KONG – A Korean study has identified a novel small-molecule chemotherapy that offers the potential to be an improved treatment option for patients with tumors having a DNA mismatch repair (MMR) deficiency, which do not respond to conventional chemotherapies. Research was published in the July 5, 2016, early online edition of Cancer Research. Read More
LONDON – Celyad SA bounced back from the phase III failure of its C-Cure stem cell therapy in congestive heart failure to seal a $311.5 million plus royalties deal with Japanese pharma Ono Pharmaceutical Co Ltd., for the development and commercialization of a preclinical-stage allogeneic T-cell immunotherapy. Read More
